CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2018--
Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on delivering innovative therapies to patients with kidney
disease through the biology of hypoxia-inducible factor (HIF), today
announced that its President and Chief Executive Officer, John P.
Butler, will present at the UBS Global Healthcare Conference on Tuesday,
May 22, 2018, at 4:00 p.m. Eastern Time, at the Grand Hyatt New York in
New York City.
A live webcast of the presentation will be available on the company’s
website at www.akebia.com.
To access the webcast, please log onto the Akebia website at least 15
minutes prior to the webcast to ensure adequate time for any software
downloads that may be required. A replay of the webcast will be
available on Akebia’s website following the conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative therapies
to patients with kidney disease through hypoxia-inducible factor
biology. For more information, please visit our website at www.akebia.com,
which does not form a part of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180515005100/en/
Source: Akebia Therapeutics, Inc.
John Garabo, 617-844-6130